CAR-T Cell and COVID-19 and how and when to restart the transplant program (EBMT/ASTCT)

When:  May 26, 2020 from 9:00 AM to 10:00 AM (CT)
Associated with  COVID-19 Resource Community

This webinar is jointly organized by EBMT and ASTCT. 

In this webinar experts from EBMT and ASTCT will report on feasibility and prevention measures of CAR-T cell treatment during COVID-19 pandemic in Europe and the US and in the second part experts will give recommendations when to restart the transplant program and when chemotherapy and/or transplant can be admitted safe in previous COVID-19 infected patients.    

Learning  objectives:

  • to describe the risk of CAR-T cell treatment during COVID-19 pandemic
  • to describe prevention measures during COVID-19 pandemic  for patients undergoing CAR-T cell treatment
  • to learn when to restart the transplant program in heavily affect COVID-19 regions
  • to learn about the timing of chemotherapy/transplantation in hematological patients previously COVID-19 infected

Moderators:

  • Nicolaus Kröger, MD: Professor of Medicine, Director Department of Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Martinistrasse 52 D-20246 Hamburg/Germany
  • Pavan Reddy, MD: Frances and Victor Ginsberg Professor of Hematology/Oncology, Professor of Medicine and Pediatrics, Chief, Division of Hematology-Oncology, Deputy Director, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA